Based on the key role of inflammatory mediators in the pathogenesis of ALI, recent treatments have been aimed at modulating TLR4 signaling and alleviating nonspecific inflammatory reactions that may result in potential therapeutic advantages for ALI. The gene discussed is TLR4; the disease is acute respiratory distress syndrome.